You are here: Home: PCU 3 | 2005: Mario A Eisenberger, MD: Select publications
Select publications
Berry WR. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology 2005;65(6 Suppl):2-7. Abstract
Doggrell SA. Which drug combination for hormone-refractory prostate cancer? Expert Opin Pharmacother 2005;6(4):667-70. Abstract
Eisenberger MA et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Presentation. ASCO 2004;Abstract 4.
Kibel AS. An interdisciplinary approach to treating prostate cancer. Urology 2005;65(6 Suppl):13-8. Abstract
Parker C, Emberton M. Prolonging survival in prostate cancer: Chemotherapy will have an important role. BJU Int 2005;96(1):2-3. No abstract available
Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005;65(6 Suppl):8-12.Abstract
Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004a;351(15):1513-20.Abstract
Petrylak DP et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). Presentation. ASCO 2004b;Abstract 3.
Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract
|
